2017 issue 2


Volume 33, issue 2

Letter to the Editor

Critical remarks to Agnieszka Piróg-Balcerzak’s, Bogusław Habrat’s, Paweł Mierzejewski’s. Niewłaściwe używanie i nadużywanie kwetiapiny. Psychiatria Polska 2015; 49 (1): 81–93

Marek Zielinski1, Piotr Sobol-Kołodziejczyk1
1. Daimler und Benz Stiftung, Ladenburg, Niemcy
Farmakoterapia w Psychiatrii i Neurologii 2017, 33 (2), 143–147
Date of publication: 20-11-2017
DOI: http://dx.medra.org/10.17393/fpn.2017.10.004


Summary of the article of Agnieszka Piróg-Balcerzak, Bogusław Habrat, Paweł Mierzejewski. Niewłaściwe używanie i nadużywanie kwetiapiny [Misuse and abuse of quetiapine]. Psychiatria Polska 2015; 49 (1): 81–93: Quetiapine (quetiapinum) is an atypical antipsychotic commonly used in psychiatry, often for symptomatic treatment of a number of mental disorders. One of the reasons for using it is the alleviation of clinical symptoms caused by the use of various psychoactive substances. The article shows and discusses reports on misuse of quetiapine, its abuse, and even psychiatric addiction as symptoms similar to those of what is known as the discontinuation syndrome, often related to withdrawal syndrome occurring with addictions. Most of the cited reports concern men – in particular those with a history of addiction to other psychoactive substances, with personality disorders or those who are in conflict with the law. Therefore, clinicians should be alert when they prescribe quetiapine to such patients. The article discusses potential mechanisms responsible for quetiapine abuse, which is most probably related to sedative and anxiolytic activity, that results in stimulation. Thus, the similarity to the H1 receptor and antihistamine agents results in satisfying action (cf. p. 81).

Address for correspondence:
Marek Zielinski
ul. A. Asnyka 9, skr. poczt. 636, 35-001 Rzeszów
phone: 0048510210887, email: mrziel@o2.pl